Helius Medical Technologies, Inc. Announces Reimbursement by Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device

Core Insights - Helius Medical Technologies has received reimbursement approval for the PoNS Device from United Healthcare, marking it as the second major healthcare provider to do so after Anthem [1][2] - The approved reimbursement amount totals $18,100, which reflects the out-of-network adjusted list price [2] Company Overview - Helius Medical Technologies is a neurotech company focused on addressing neurologic deficits through its Portable Neuromodulation Stimulator (PoNS) [3] - The PoNS device is designed to improve balance and gait deficits, particularly in patients with multiple sclerosis (MS) [4] Product Details - The PoNS Device is a non-implantable therapy that delivers neurostimulation via a mouthpiece, intended for use alongside physical rehabilitation exercises [4] - It is indicated for short-term treatment of gait deficits due to mild-to-moderate MS symptoms and is prescribed for patients aged 22 and older [4] Clinical Validation - The PoNS Device has demonstrated effectiveness in treating gait and balance issues, significantly reducing fall risks in stroke patients in Canada [5] - It has received authorization for multiple indications in Canada and is also approved for use in Australia [5]